<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Doses: renal impairment; Glomerular filtration rate, dosage and; Modification of Diet in Renal Disease study (‘MDRD formula’); Creatinine clearance, dosage and; Cockroft and Gault formula" /><meta name="IX" content="Doses: renal impairment; Glomerular filtration rate, dosage and; Modification of Diet in Renal Disease study (‘MDRD formula’); Creatinine clearance, dosage and; Cockroft and Gault formula" /><title>Principles of dose adjustment in renal impairment: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP107-principles-of-dose-adjustment-in-renal-impairment.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP107-principles-of-dose-adjustment-in-renal-impairment.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP107-principles-of-dose-adjustment-in-renal-impairment.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 12 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP59-guidance-on-prescribing.htm">Guidance on prescribing</a> &gt; <a href="PHP106-prescribing-in-renal-impairment.htm">Prescribing in renal impairment</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP106-prescribing-in-renal-impairment.htm" title="Previous: Prescribing in renal impairment">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP111-prescribing-in-pregnancy.htm" title="Next: Prescribing in pregnancy">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Principles of dose adjustment in renal impairment</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p>The level of renal function below which the dose of a drug must be reduced depends on the proportion of the drug eliminated by renal excretion and its toxicity.</p><p>For many drugs with only minor or no dose-related side-effects very precise modification of the dose regimen is unnecessary and a simple scheme for dose reduction is sufficient.</p><p>For more toxic drugs with a small safety margin or patients at extremes of weight, dose regimens based on creatinine clearance (see <a title="BNF:target-block: Renal function measurement" href="PHP107-principles-of-dose-adjustment-in-renal-impairment.htm#PHP108">below</a> for details) should be used. When both efficacy and toxicity are closely related to plasma-drug concentration, recommended regimens should be regarded only as a guide to initial treatment; subsequent doses must be adjusted according to clinical response and plasma-drug concentration.</p><p>Renal function declines with age; many elderly patients have renal impairment but, because of reduced muscle mass, this may not be indicated by a raised serum creatinine. It is wise to assume at least mild impairment of renal function when prescribing for the elderly.</p><p>The total daily maintenance dose of a drug can be reduced either by reducing the size of the individual doses or by increasing the interval between doses. For some drugs, although the size of the maintenance dose is reduced it is important to give a loading dose if an immediate effect is required. This is because it takes about five times the half-life of the drug to achieve steady-state plasma concentrations. Because the plasma half-life of drugs excreted by the kidney is prolonged in renal impairment it can take many doses for the reduced dosage to achieve a therapeutic plasma concentration. The loading dose should usually be the same size as the initial dose for a patient with normal renal function. </p><p><strong>Nephrotoxic drugs</strong> should, if possible, be avoided in patients with renal disease because the consequences of nephrotoxicity are likely to be more serious when renal reserve is already reduced.</p><p id="PHP108">Dose recommendations are based on the severity of renal impairment.</p> <p>Renal function is measured either in terms of estimated <strong>glomerular filtration rate</strong> (eGFR) calculated from a formula derived from the Modification of Diet in Renal Disease study (‘MDRD formula’ that uses serum creatinine, age, sex, and race (for Afro-Caribbean patients)) or it can be expressed as <strong>creatinine clearance</strong> (best derived from a 24-hour urine collection but often calculated from the Cockcroft and Gault formula (CG).</p> <div class="table" id="PHP109"> <div class="cAA">Cockcroft and Gault formula</div> <table class="table" summary="Cockcroft and Gault formula" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; "><colgroup><col /><col /><col /></colgroup><tbody><tr><td style="" rowspan="2">Estimated Creatinine Clearance in mL/minute</td><td style="text-align: center;vertical-align: middle;" rowspan="2">=</td><td style="border-bottom: 1pt solid ; ">(140 – Age) × Weight × Constant</td></tr><tr><td style="text-align: center;">Serum creatinine</td></tr><tr><td style=""><div class="cF"><p>Age in years</p><p>Weight in kilograms; use ideal body-weight</p><p>Serum creatinine in micromol/litre</p><p>Constant = 1.23 for men; 1.04 for women</p></div></td><td class="auto-generated" style=""> </td><td class="auto-generated" style=""> </td></tr></tbody></table></div> <p>The serum-creatinine concentration is sometimes used instead as a measure of renal function but it is only a <strong>rough guide</strong> to drug dosing.</p> <div class="cI"><h3 class="cT">Important</h3><p>Renal function in adults is increasingly being reported on the basis of estimated glomerular filtration rate (eGFR) normalised to a body surface area of 1.73 m<sup>2</sup> and derived from the Modification of Diet in Renal Disease (MDRD) formula. However, published information on the effects of renal impairment on drug elimination is usually stated in terms of creatinine clearance as a surrogate for glomerular filtration rate (GFR). </p><p>The information on dosage adjustment in the BNF is expressed in terms of eGFR, rather than creatinine clearance, for most drugs (see exceptions below: Toxic Drugs and Patients at Extremes of Weight). Although the two measures of renal function are not interchangeable, in practice, for most drugs and for most patients (over 18 years) of average build and height, eGFR (MDRD ‘formula’) can be used to determine dosage adjustments in place of creatinine clearance. An individual's absolute glomerular filtration rate can be calculated from the eGFR as follows:<br />GFR <sub>Absolute</sub> = eGFR × (individual's body surface area/1.73)</p> <h3 class="cT">Toxic drugs</h3><p>For potentially toxic drugs with a small safety margin, creatinine clearance (calculated from the Cockcroft and Gault formula) should be used to adjust drug dosages in addition to plasma-drug concentration and clinical response.</p> <h3 class="cT">Patients at extremes of weight</h3><p>In patients at both extremes of weight (BMI of less than 18.5 kg/m<sup>2</sup> or greater than 30 kg/m<sup>2</sup>) the absolute glomerular filtration rate or creatinine clearance (calculated from the Cockcroft and Gault formula) should be used to adjust drug dosages.</p> </div> <p>In the BNF, values for eGFR, creatinine clearance (for toxic drugs), or another measure of renal function are included where possible. However, where such values are not available, the BNF reflects the terms used in the published information.</p> <p><em>Chronic kidney disease in adults: UK guidelines for identification, management and referral (March 2006)</em> define renal function as follows:</p> <div class="table" id="PHP110"><table class="table" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; border-left: 1pt solid ; border-right: 1pt solid ; "><colgroup><col /><col /></colgroup><thead><tr><th style="border-right: 1pt solid ; ">Degree of impairment</th><th style="border-right: 1pt solid ; ">eGFR mL/minute/1.73 m<sup>2</sup></th></tr></thead><tbody><tr><td style="border-right: 1pt solid ; ">Normal - Stage 1</td><td style="border-right: 1pt solid ; ">More than 90 (with other evidence of kidney damage)</td></tr><tr><td style="border-right: 1pt solid ; ">Mild - Stage 2</td><td style="border-right: 1pt solid ; ">60–89 (with other evidence of kidney damage)</td></tr><tr><td style="border-right: 1pt solid ; ">Moderate<sup>1</sup> - Stage 3</td><td style="border-right: 1pt solid ; ">30–59</td></tr><tr><td style="border-right: 1pt solid ; ">Severe - Stage 4</td><td style="border-right: 1pt solid ; ">15–29</td></tr><tr><td style="border-right: 1pt solid ; ">Established renal failure - Stage 5</td><td style="border-right: 1pt solid ; ">Less than 15</td></tr><tr><td style="border-right: 1pt solid ; "><div class="cF"><p>1. NICE clinical guideline 73 (September 2008)—Chronic kidney disease: Stage 3A eGFR 45–59, Stage 3B eGFR 30–44</p></div></td><td class="auto-generated" style="border-right: 1pt solid ; "> </td></tr></tbody></table></div> <div class="cI"><h3 class="cT">Dialysis</h3><p>For prescribing in patients on continuous ambulatory peritoneal dialysis (CAPD) or haemodialysis, consult specialist literature.</p></div><p>Drug prescribing should be kept to the minimum in all patients with severe renal disease.</p><p>If even mild renal impairment is considered likely on clinical grounds, renal function should be checked before prescribing <strong>any</strong> drug which requires dose modification.</p><p>Where care is needed when prescribing in renal impairment, this is indicated under the relevant drug in the BNF.</p></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP106-prescribing-in-renal-impairment.htm">Previous: Prescribing in renal impairment</a> | <a class="top" href="PHP107-principles-of-dose-adjustment-in-renal-impairment.htm#">Top</a> | <a accesskey="]" href="PHP111-prescribing-in-pregnancy.htm">Next: Prescribing in pregnancy</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>